Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Sichuan Jiuzhang Biological Science And Technology Co. Ltd. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, BELL, SARA ELIZABETH. The concentration of the portfolio is reflected in the use of 1 distinct art unit for all current activity. BELL, SARA ELIZABETH serves as the busiest examiner for the company, overseeing 1 busiest examiner pending action.
The alignment of the 1 pending office action with a single examiner suggests a highly focused prosecution front. Because the company utilizes only 1 distinct art unit, the technical scope of its current legal efforts is limited to a specific niche. Practitioners should note that with the 1 busiest examiner pending action, the examiner BELL, SARA ELIZABETH holds total influence over the company's immediate outcomes. This centralized structure means that any specific preferences of the 1 distinct examiner will impact the entire pending portfolio. Such a concentrated strategy requires precise coordination with the assigned staff to ensure consistent progress across the Biotechnology & Pharmaceuticals filings.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BELL, SARA ELIZABETH | 1 | 68.8% | +38.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18577383 | USE OF CHLOROGENIC ACID IN PREPARATION OF MEDICINE FOR TREATING CENTRAL NERVOUS SYSTEM TUMOR | BELL, SARA ELIZABETH | 28d |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18577383 | USE OF CHLOROGENIC ACID IN PREPARATION OF MEDICINE FOR TREATING CENTRAL NERVOUS SYSTEM TUMOR | BELL, SARA ELIZABETH | 1625 | §102§103§112DP | Final Rejection | 28d | Pending | Jan 08, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial